Adipotide (FTPP)
Adipotide is a ligand-directed peptidomimetic: a cyclic CKGGRAKDC motif binds prohibitin on the endothelial cells that line white-adipose-tissue blood vessels, and a fused proapoptotic D(KLAKLAK)2 sequence disrupts mitochondrial membranes once internalized. This triggers apoptosis of the fat's vascular supply, producing ischemic atrophy of white fat depots rather than appetite suppression. The same delivery to renal tissue underlies the dose-dependent, reversible kidney effects seen in primates.
Metabolic effects build over days to weeks of consistent use.
Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.
Clinical Evidence
What the literature says
Scientific Overview
According to PubMed, adipotide induced targeted apoptosis in white-fat blood vessels and produced rapid weight loss and improved insulin resistance in obese Old World monkeys, but at higher doses caused predictable, reversible renal proximal-tubule changes (Barnhart KF et al., Sci Transl Med 2011). Human data are limited to a Phase 1 dose-finding/safety study (NCT01262664) in patients with obesity and metastatic prostate cancer; development has not advanced publicly. It is investigational only.
Pharmacokinetics
- Routes
- Subcutaneous
Citations (2)
Last reviewed: 2026-06-15
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Typical Dose Range Observed
Research Protocols
Common DosagesPhase 1 (human, safety)
“Dose-finding/safety only (NCT01262664); investigational”
Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.
Reported Uses
- Investigational targeted fat loss (preclinical and Phase 1 only)
- Research into adipose-vasculature-directed therapy
- Tool compound for prohibitin biology
Key Research Benefits
- Preclinical: targeted destruction of white-fat vasculature causing fat loss
- Preclinical: weight loss and improved insulin resistance in obese monkeys
- Mechanistically distinct from appetite-based fat-loss agents
Potential Side Effects
Considerations and Cautions
- No established human safety; not for use outside research
- Renal impairment (dose-dependent renal toxicity seen in primates)
- Pregnancy or breastfeeding (no data)
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- Renal function (creatinine, BUN, urinalysis): Dose-dependent, reversible renal proximal-tubule effects were the key safety signal.
- Body weight / composition: Primary efficacy measure in studies.
- Fasting glucose / insulin (HOMA-IR): Metabolic effect observed in primate studies.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.10 mL on a U-100 syringe
Adipotide (FTPP) by goal
Read Adipotide (FTPP)'s profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.